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Highlights 
- Single dose of intranasal oxytocin has little to no effect on emotional theory 
of mind or emotion expression among healthy or clinical adult populations  
- Intranasal oxytocin improved recognition of basic emotions, particularly 
fear, but only among healthy populations 
- Intranasal oxytocin improves sensitivity to recognise anger, but only 
among healthy populations 
- Effect of oxytocin may be dependent on social boundaries 
 
 
1 Abstract 
Accurate interpretation and appropriate expression of emotions are key aspects of 
social-cognition. Several mental disorders are characterised by transdiagnostic 
difficulties in these areas and, recently, there has been increasing interest in exploring 
the effects of oxytocin on social-emotional functioning. 
 
This review consists of 33 studies. Fifteen of the studies included people with autism 
spectrum disorder, schizophrenia, borderline personality disorder, frontotemporal 
dementia, anorexia nervosa, bulimia nervosa, post-traumatic stress disorder, 
depression, and opioid and alcohol dependence. We conducted ten meta-analyses 
examining the effects of intranasal oxytocin on expression of emotions, emotional 
theory of mind, sensitivity to recognise basic emotions, and recognition of basic 
emotions.  
 
A single dose of intranasal oxytocin significantly improved the recognition of basic 
emotions, particularly fear, and increased the expression of positive emotions among 
the healthy individuals. Oxytocin did not significantly influence theory of mind or the 
expression of negative emotions among the healthy individuals. Finally, intranasal 
oxytocin did not significantly influence interpretation or expression of emotions 
among the clinical populations.  
 
Keywords: oxytocin, theory of mind, emotion recognition, emotion expression 
  
2 Introduction 
Accurate interpretation of other’s emotions, appropriate expression of one’s own 
emotions, and reciprocity within interactions are key aspects of social cognition. In 
social interaction, emotion expression is dependent on accurate interpretation of 
social signals (Hess and Fischer, 2013; Künecke et al., 2014). According to the 
embodied simulation theory, emotion expression and mimicry, in turn, play an 
important role in facilitating the interpretation of others’ expressions, empathy, and 
prosocial behaviour in recipients (Gallese, 2005). Indeed, behavioural studies have 
documented that automatic mimicry of emotions facilitates recognition, whereas 
blocking mimicry impairs recognition accuracy and sensitivity (Argaud et al., 2016; 
Duffy and Chartrand, 2015; Künecke et al., 2014; Rychlowska et al., 2014; Schneider 
et al., 2013). Anomalies in emotion expression also have social and affective 
consequences, with incongruent emotion expression increasing the desire for greater 
social distance and negative social evaluation by the recipient (Brown et al., 2015; 
Szczurek et al., 2012). Similarly, expressive suppression has been found to increase 
the suppressors’ blood pressure, subjective anxiety, and social isolation (Butler et al., 
2003; Gross, 2002).  
 
Anomalies in social-emotional functioning are important transdiagnostic features in 
several psychiatric disorders (Bora and Berk, 2016; Bora and Köse, 2016; Chung et al., 
2014; Davies et al., 2016; Henry et al., 2014; Kring and Moran, 2008). Meta-analyses 
have found that people with eating disorders (EDs), depression, schizophrenia, and 
autism spectrum disorders (ASD) have similar difficulties in accurate interpretation of 
emotions, including recognition of basic emotions in faces and tone of voice with small 
effect sizes and in emotional theory of mind with medium to large effect sizes (Bora 
and Berk, 2016; Bora and Köse, 2016; Caglar-Nazali et al., 2014; Chung et al., 2014; 
Uljarevic and Hamilton, 2013). Recent systematic reviews have also found that people 
with schizophrenia, EDs, depression, ASD, and borderline personality disorder (PBD) 
display less positive facial affect in response to positive emotional stimuli (Davies et 
al., 2016; Kring and Moran, 2008). Furthermore, a recent meta-analysis of 537 task-
based fMRI studies in depression, bipolar disorder, schizophrenia, and obsessive-
compulsive disorder failed to find significant differences between the disorders in 
whole brain neural response to social and cognitive tasks (Sprooten et al., 2016). 
Together these findings suggest that anomalies in social-emotional processing in 
psychiatric disorders may have shared underlying mechanisms. Given social and 
affective consequences of these difficulties, better understanding of the underlying 
processes is of interest. One such possible mechanism is the oxytocin system.  
 
Preclinical studies have found that the neuropeptide, oxytocin, may regulate social-
emotional functioning (Dölen et al., 2013; Hicks et al., 2012; Lim and Young, 2006; 
Lukas et al., 2011; Onaka et al., 2012). Endogenous oxytocin has been found to play 
an important role in the central and medial amygdala, facilitating formation of social 
bonds, maternal behaviour, and social recognition in rodents (Lim and Young, 2006; 
Onaka et al., 2012). Additionally, a recent study found that formation of social reward 
was dependent on coordinated activity between oxytocin and serotonin in the mouse 
nucleus accumbens (Dölen et al., 2013).  In rodents, the administration of oxytocin 
receptor agonist and exogenous synthetic oxytocin has also been found to increase 
social place preference and reduce social defeat induced avoidance (Hicks et al., 2012; 
Lukas et al., 2011). Conversely, the administration of oxytocin receptor antagonist, has 
been found to increase corticosteroid levels and induce social avoidance in monkeys 
during times of stress (Cavanaugh et al., 2016).  
 
Recently there has been increasing interest in translating these findings into humans 
and the effects of intranasal oxytocin on social-emotional function  has been widely 
studied (Bakermans-Kranenburg and van Ijzendoorn, 2013; Bartz et al., 2011; 
Guastella and MacLeod, 2012; Shahrestani et al., 2013; van Ijzendoorn and 
Bakermans-Kranenburg, 2012). A few previous meta-analytic reviews have found that 
intranasal oxytocin improves recognition of anger and happiness, and increases in-
group trust among healthy individuals with small effect sizes (Shahrestani et al., 2013; 
van Ijzendoorn and Bakermans-Kranenburg, 2012). However, to our knowledge no 
meta-analyses to date have investigated the effects of a single dose of oxytocin on 
recognition of all six basic emotions, other aspects of emotion interpretation, 
including theory of mind or sensitivity to recognise basic emotions, or on emotion 
expression among healthy individuals.  
 
To date, two meta-analytic reviews have investigated the effects of intranasal 
oxytocin on different aspects of social-emotional functioning in a variety of clinical 
groups (Bakermans-Kranenburg and van Ijzendoorn, 2013; Ooi et al., 2017). One 
reported small, but generally positive effect of intranasal oxytocin on social-emotional 
functioning and psychopathology among people with ASD, anxiety disorders, 
depression, schizophrenia, and BPD (Bakermans-Kranenburg and van Ijzendoorn, 
2013; Ooi et al., 2017). The other meta-analysis found no significant effects of 
intranasal oxytocin on social-emotional processing in ASD (Ooi et al., 2017). However, 
these reviews were quite heterogeneous pooling studies assessing psychopathology 
and social-emotional processing, or single dose and repeated dose studies into one 
meta-analysis (Bakermans-Kranenburg and van Ijzendoorn, 2013; Ooi et al., 2017). To 
our knowledge no previous meta-analyses have investigated the effects of a single 
dose of intranasal oxytocin separately on different aspects of interpretation and 
expression of emotions among both healthy and clinical populations. In order to 
consider the possibility of translating animal studies more widely into treatment for 
psychiatric disorders it is important to consider various key outcomes and whether 
there is evidence that they might be modified by oxytocin. 
 
The aim of the current review was to pool studies investigating the effects of a single 
dose of intranasal oxytocin on various aspects of social-emotional functioning among 
healthy and clinical populations. Specifically, we aimed to examine the effects of 
intranasal oxytocin on theory of mind, recognition of basic emotions, sensitivity to 
recognise basic emotions, and on emotion expression among healthy and clinical 
populations. We tested the hypothesis that oxytocin would improve all aspects of 
social-emotional functioning. 
 
3 Methodology 
 
3.1 Literature searches 
Electronic databases, including OVID (journals@OVID, PsycINFO, PsycARTICLES, 
Embase, AGRIS, MEDLINE), PubMed, and Web of Knowledge core collection, were 
searched for studies published during available years up to February 2017 in 
accordance with the PRISMA guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009). 
Two separate literature searches were conducted in order to uncover studies 
investigating the effects of a single dose of intranasal oxytocin on interpretation and 
expression of emotions in a social context. The first literature search was conducted 
with the following search terms: oxytocin AND emotion AND (interpretation OR 
recognition OR identification OR labelling OR “theory of mind” OR mentalising OR 
perception OR empath*). The second search was conducted with the following search 
terms: oxytocin AND emotion AND (expression OR mimicry OR mirroring OR 
communication OR responsiveness OR expressivity). Additionally, to ensure no studies 
were missed by the initial search, the bibliographies of included studies were searched 
for additional studies.  
 
 
3.2 Eligibility criteria 
Studies were included if they met the following inclusion criteria: 1) investigated the 
effects of a single dose of intranasal exogenous oxytocin on interpretation or 
expression of emotions in a social context among either healthy adult participants or 
adult clinical populations (18 years old or older); 2) compared the effects of intranasal 
oxytocin with intranasal placebo spray; 3) investigated short term outcomes; and 4) 
randomly allocated participants to oxytocin and placebo groups or, in the case of 
crossover, within subjects studies, randomised the treatment order. Any studies, 
which used tasks that did not include a social component, such as the bumper car 
theory of mind task where social context is inferred from the movement of triangles 
on a computer screen, were excluded. Trials, in which participants either received 
repeated doses of oxytocin or in which long term outcomes of a single dose of oxytocin 
were assessed, were excluded. Studies that included only children or adolescents 
were excluded, because the majority of them were longer trials and the effects of 
oxytocin on social-emotional processing can be different in adults and children. Full-
text articles published in peer reviewed journals and where possible, published 
conference abstracts were included.  
 
 
In total, five studies were excluded after further screening because they incorporated 
tasks that were very different compared to the other included studies despite being 
otherwise relevant. These studies included a theory of mind task involving infant 
stimuli, continuously assessing the mood of a target on a video clip on a 9-point Likert 
scale, manipulating the context in which the emotions were presented, recognising 
emotions from a point-light-display, and interpreting basic emotions from tone of 
voice in different languages (Bartz et al., 2010; Bernaerts et al., 2016; De Dreu et al., 
2016; Perry et al., 2013; Voorthuis et al., 2014).  
 
3.3 Study selection 
The literature searches were conducted by one author (J.L.). The studies yielded from 
the literature search were then screened based on their titles and abstracts. Full text 
articles were then assessed for eligibility followed by final screening and assessment 
by two authors (J.L. and K.W.N.). Where appropriate conference abstracts of studies 
not yet published were also screened and assessed for eligibility. If deemed eligible 
the authors were contacted in order to gain access to the data. Only studies that both 
authors agreed on were included in the final systematic review and meta-analyses. 
Any cases where eligibility remained in question were brought to the whole team for 
further discussion and assessment. The study selection processes of the two searches 
are presented in Figures 1 and 2.  
 
Figure 1. PRISMA flow chart of selection of articles for interpretation of emotions 
-------------------------------------------------FIGURE 1--------------------------------------------------- 
  
Figure 2. PRISMA flow chart of selection of articles for expression of emotions 
-------------------------------------------------FIGURE 2--------------------------------------------------- 
 
 
3.4 Data collection and synthesis 
Seventeen studies reported their results in figures or otherwise did not include the 
relevant data in the paper or supplementary materials. The corresponding authors of 
these papers were contacted by K.W.N. in order to gain access to the relevant data. 
The authors of the following papers provided the required data via personal 
correspondence: Aoki et al. (2014), Averbeck et al. (2012), Cardoso et al. (2014a), Chen 
et al. (2015),  Fischer-Shofty et al. (2010), Kirkpatrick et al. (2014), Koch et al. (2016), 
Korb et al. (2016), and Luminet et al. (2011). 
 In order to conduct meta-analyses means, standard deviations, and samples sizes for 
both oxytocin and placebo groups or sessions were extracted from the studies or 
acquired through personal correspondence. Where standard error of the mean was 
reported, standard deviation was estimated with the following formula 𝑆𝐷 =  𝑆𝐸 ∗
√𝑁. Altogether ten meta-analyses were conducted to investigate the effects of a 
single dose of intranasal oxytocin on interpretation and expression of emotions. The 
first meta-analysis investigated the effects of intranasal oxytocin on emotional theory 
of mind among healthy and clinical populations. The second meta-analysis 
investigated the effects of a single dose of intranasal oxytocin on interpretation of 
basic emotions among healthy and clinical populations. Five out of fifteen studies 
included in the overall basic emotion recognition meta-analysis included all six basic 
emotions. Thus, to provide further information about the effects of intranasal 
oxytocin on each of the six basic emotions, separate meta-analyses were conducted 
on recognition of anger, fear, disgust, sadness, surprise, and happiness among healthy 
and clinical populations. The last two meta-analyses investigated the effects of 
intranasal oxytocin on emotion recognition sensitivity and expression of congruent 
emotions in response to emotionally provoking stimuli. The clinical category included 
people with ASD, schizophrenia, depression, anorexia nervosa (AN), bulimia nervosa 
(BN), BPD, behavioural variant of frontotemporal dementia (FTD), alcohol 
dependence disorder, and opioid dependence disorder.  
 
Additional information regarding age, the oxytocin dose (in international units [IU]), 
the specific diagnosis of clinical participants, the proportion of female participants in 
the sample, and type of task used were also recorded. We also included information 
regarding the presence of ceiling effects in accuracy scores. Since there are currently 
no guidelines to indicate what should be used as a cut-off for ceiling effects, we chose 
an arbitrary cut-off of 85%. Studies, in which the accuracy scores were greater than or 
equal to 85%, were coded as having evidence of ceiling effects. The additional 
information was used to conduct meta-regressions to identify variables that might 
explain any potential between-study heterogeneity.  
 
3.5 Emotion interpretation tasks 
The emotion interpretation tasks included are summarised in Table 1. The theory of 
mind tasks included the Reading the Mind in the Eyes task (RMET) (Baron-Cohen et 
al., 2001), Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) (Mayer et al., 
2003), The Awareness of Social Inference Test (TASIT) (McDonald et al., 2003), and the 
Sally Anne task (Baron-Cohen et al., 1985). In the RMET participants are presented 
with 36 photographs of eyes and asked to select one of four words that best describes 
the complex emotion displayed. The MSCEIT has six subscales, three of which were of 
interest for the current review and assessed perception of emotions in others and 
understanding of how emotions change and blend together. The TASIT has three 
subscales, two of which were of interest for the current review and assessed 
emotional evaluation and social-emotional inference based on verbal and visual 
stimuli. Finally, the Sally Anne task assesses emotional and cognitive theory of mind 
with black and white comic strips. The current reviewed only included data on 
emotional theory of mind.  
 
The studies that investigated the effects of a single dose of intranasal oxytocin on 
interpretation of basic emotions mostly used standard emotion recognition 
paradigms in which participants were presented with a photograph of a face depicting 
a basic emotion and asked to identify the emotion. A subset of studies used dynamic 
emotion recognition tasks, in which participants were presented with a neutral face 
that gradually morphed into the full emotion, or masked emotion recognition tasks, 
in which the photograph of a face depicting a basic emotion was either preceded or 
followed by a neutral face. The outcome was recognition accuracy. All studies used 
standardised stimuli to assess emotion recognition accuracy. 
 
All studies examining interpretation sensitivity used similar dynamic emotion 
recognition tasks as described above. In these tasks participants were initially 
presented with a neutral face that gradually morphed into full emotion. The outcome 
was estimated as the intensity percentage at which participants accurately recognised 
the emotion. Lower the intensity percentage, the more sensitive the participants were 
to detect the emotion. All studies used standardised stimuli to assess emotion 
recognition sensitivity.  
 
3.6 Emotion expression tasks 
The emotion expression tasks included are summarised in Table 1. All included studies 
used different paradigms to elicit positive and negative emotions. One of the studies 
presented participants with emotionally provoking positive and negative images from 
the International Affective Picture System (IAPS). Two of the studies presented 
participants with short film clips. In one study the film clips depicted either a happy 
face that gradually morphed into an angry expression or an angry face that gradually 
morphed into a happy expression. The other study presented participants with 
excerpts from movies that were designed to elicit happy and sad emotions. Lastly, one 
study assessed expressions of flight and affiliation during a clinical interview. 
Participants facial expression were recorded either by manually assessing facial 
expression using the Facial Expression Coding System (FACES, (Kring and Sloan, 1991)), 
using facial electromyography (EMG), or using automated facial emotion detection 
software, Noldus FaceReader (Noldus Information Technology b.v., www.noldus.com).  
 
3.7 Statistical analysis 
All statistical analysis was performed using R (R Core Team, 2015). For studies using 
between subjects design Hedges’ g was calculated to estimate unbiased effect size 
with 95% confidence intervals. For studies using within subjects design standardised 
mean change (SMC) with change score standardisation was calculated to estimate 
effect size with 95% confidence intervals. The SMC controls for the correlation in task 
performance between the two assessments (oxytocin session and placebo session). 
Where correlation between the two assessments was not reported, the correlation 
coefficient was estimated using the following formula 𝑟 =
𝑆𝐷12+𝑆𝐷22−𝑆𝐷𝑐ℎ𝑎𝑛𝑔𝑒2
2×𝑆𝐷1×𝑆𝐷2
  
(Morris and DeShon, 2002). Both Hedges’ g and SMC effect size estimates was are on 
the same scale and were interpreted as small (≥0.20), medium (≥0.50), and large 
(≥0.80) (Hedges, 1981).  In nine of the ten meta-analyses higher scores indicated either 
greater accuracy or greater facial expressivity. Thus, in these meta-analyses positive 
effect size indicated improved emotion interpretation accuracy or increased emotion 
expression following oxytocin administration, whereas negative effect size indicated 
poorer emotion interpretation or reduced emotion expression following oxytocin 
administration. In the meta-analysis investigating emotion recognition sensitivity 
lower scores indicated greater sensitivity to recognise the facial expressions. Thus, in 
this meta-analysis negative effect sizes indicated increased sensitivity to recognise 
emotions following oxytocin administration and positive effect sizes indicated 
reduced sensitivity to recognise emotions following oxytocin administration. 
Significance threshold was set at p < 0.05 unless otherwise stated. 
 
The user contributed Metafor package was used to conduct the meta-analyses, meta-
regressions, and publication bias estimation (Viechtbauer, 2010). The meta-analyses 
were conducted with a multivariate random effects model with an autoregressive 
structure using the rma.mv function in Metafor to account for correlations arising 
from multiple outcomes from the same sample. Between-study heterogeneity was 
assessed by calculating Cochran’s Q index and I² index. Where between-study 
heterogeneity was found meta-regressions were conducted and the moderator 
effects of the following variables was assessed: age, the dose administered (in IU), 
specific diagnosis of clinical participants, the type of task used, the proportion of 
female participants in the sample, and whether there were ceiling effects present 
(accuracy ≥ 85%). All binary and categorical moderators were dummy coded and 
entered into the meta-regression using the factor function. The impact of each 
moderator was assessed in separate models. 
 
Influential studies and extreme outliers were identified by inspecting Cook’s distance 
plots and the standardised residuals of each individual study. Where the z-score of the 
standardised residuals exceeded 1.96, the study was deemed to be an outlier 
(Viechtbauer and Cheung, 2010). To test the impact of any outliers on the pooled 
effect size estimate, we conducted the meta-analysis with the outlier present followed 
by a meta-regression to examine whether the outlier significantly explained the 
between study heterogeneity. If the outlier significantly explained the heterogeneity, 
the outlier was excluded and only results from the meta-analysis without the outlier 
were reported in full. This procedure led to exclusion of one study (Xu et al., 2015) 
from two separate meta-analyses.  
 
Publication bias was investigated with Begg's rank correlation test for funnel plot 
asymmetry (Begg and Mazumdar, 1994) and where significant effects were present 
Rosenthal’s file drawer analysis was also conducted (Rosenthal, 1979). The robustness 
of the significant findings was assessed by calculating the Rosenthal’s criterion (5n+10, 
n = the number of studies in the meta-analysis) and comparing that figure to the fail-
safe N from the file drawer analysis. If the fail-safe N exceeded the criterion the 
findings were considered robust, if it did not this was taken as an indicator of 
publication bias.  
 
Finally, the statistical power of each study included in the review was assessed by 
comparing the sample sizes in these studies against that recommended by a power 
calculation conducted with G*Power (Faul et al., 2007). According to the power 
calculation studies using between subjects design should have at least 64 participants 
in each group while studies using within subjects design should have at least 34 
participants altogether, to have adequate statistical power (≥80%) to reliably detect a 
moderate difference (ES ≥ 0.5) between the two groups or conditions.  
 
4 Results 
 
4.1 Study characteristics 
The characteristics of the 33 included studies are summarised in Table 1. The effect 
size estimate (ES) represents standardised mean difference (Hedges’ g) or 
standardised mean change (SMC) in interpretation and expression of emotions 
following oxytocin and placebo. The last column in Table 1 indicates whether the study 
met the sample size requirement for adequate statistical power (≥80%) to reliably 
detect at least a medium sized effect between the oxytocin and placebo groups or 
conditions. None of the studies that used between subjects design met the 
requirement for adequate power, but five of the studies that used within subjects 
design did meet this requirement.  
 
Table 1. Study characteristics 
-----------------------------------------------------TABLE 1------------------------------------------------- 
4.2 Effects of oxytocin on interpretation of emotions 
4.2.1 Theory of mind 
Fourteen studies were included in the meta-analysis investigating the effects of a 
single dose of intranasal oxytocin on emotional theory of mind (Figure 3). Six of the 
studies included clinical populations, namely individuals with ASD, AN, depression, 
schizophrenia, and FTD, and two studies included individuals with substance 
dependence disorder, including opioid and alcohol dependence. Overall, there was no 
significant effect of oxytocin on theory of mind (ES = 0.09, Z = 1.14, p = 0.256, 95% CI 
[-0.06, 0.24], k = 23, N of levels = 17). When the healthy and clinical groups were 
inspected separately there was no evidence of significant effect of intranasal oxytocin 
on emotional theory of mind within either group (Healthy: ES = 0.07, Z = 0.76, p = 
0.447, 95% CI [-0.10, 0.24], k = 13, N of levels = 9; Clinical: ES = 0.10, Z = 0.74, p = 0.457, 
95% CI [-0.17, 0.37], k = 10, N of levels = 8). 
 
There was evidence of significant between-study heterogeneity (Q = 65.85, p < 0.0001, 
I2 = 58.42%), which was further explored with meta-regressions. The findings from the 
meta-regressions were corrected for multiple comparisons with Bonferroni correction 
(0.05/6) and p < 0.008 was considered significant. The meta-regressions revealed a 
significant moderator effect of age (Qm = 7.33, p = 0.007; Supplementary Figure 1), 
still leaving some residual heterogeneity (Qr = 34.26, p = 0.012). This finding suggests 
that younger participants showed greater oxytocin-induced improvement in 
emotional theory of mind. The dose administered (Qm = 1.04, p = 0.309; 
Supplementary Figure 2), the type of task used (Qm = 2.78, p = 0.427), the diagnostic 
group (Qm = 0.01, p = 0.918), and the proportion of female participants in the sample 
(Qm = 1.36, p = 0.243; Supplementary Figure 3) did not significantly explain the 
between-study heterogeneity.  
 
Begg’s rank correlation test of funnel plot asymmetry approached significance 
suggesting there may have been some publication bias (T = 0.29, p = 0.057; 
Supplementary Figure 4).  
 
Figure 3. Effects of oxytocin on theory of mind 
-------------------------------------------------FIGURE 3--------------------------------------------------- 
 
4.2.2 Recognition of basic emotions 
Seventeen studies investigated the effects of intranasal oxytocin on total basic 
emotion recognition accuracy. Based on standardised residuals and Cook’s distance, 
one study by Xu et al. (2015) was identified as an extreme outlier (standardised res. = 
2.68, Z = 4.56, SE = 0.59; Supplementary Table 1; Supplementary Figure 5). The impact 
of the outlier on the meta-analysis was investigated by conducting a meta-analysis 
with the outlier present, which yielded a significant oxytocin-induced improvement in 
recognition of basic emotions with a small effect size along with significant between-
study heterogeneity (ES = 0.28, Z = 2.56, p = 0.011, 95% CI [0.07, 0.50], k = 33, N of 
levels = 23, Q = 99.98, p < 0.0001, I2 = 81.12%). We then investigated whether the 
outlier was significantly different from the other studies by conducting a meta-
regression, which revealed that the outlier significantly explained the between-study 
heterogeneity (Qm = 46.98, p < 0.0001) leaving no significant residual heterogeneity 
(Qr = 43.51, p = 0.067). Therefore, the outlier was removed from further analysis.  
 
Full meta-analysis was conducted with the remaining sixteen studies (Figure 4). Five 
of the studies included clinical populations, namely people with schizophrenia, BPD, 
ASD, and post-traumatic stress disorder. The meta-analysis revealed that intranasal 
oxytocin administration improved overall basic emotion interpretation accuracy with 
a negligible effect size (ES = 0.18, Z = 3.09, p = 0.002, 95% CI [0.06, 0.29], k = 32, N of 
levels = 22). When the effects of intranasal oxytocin on basic emotions recognition 
were further investigated within the healthy and clinical populations, the results 
showed that oxytocin significantly improved basic emotion recognition among the 
healthy individuals with a negligible effect size (ES = 0.13, Z = 2.30, p = 0.022, 95% CI 
[0.02, 0.24], k = 23, N of levels = 17). Among the mixed clinical population oxytocin-
induced improvement on basic emotion recognition approached significance with a 
small effect size (ES = 0.27, Z = 1.82, p = 0.069, 95% CI [-0.02, 0.57], k = 9, N of levels = 
5).  
 
The between-study heterogeneity approached significance (Q = 42.08, p = 0.089, I2 = 
30.27%), and was therefore, explored further with meta-regressions. The findings 
from the meta-regressions were corrected for multiple comparisons with Bonferroni 
correction (0.05/7) and p < 0.007 was considered significant. The proportion of female 
participants in the sample (Qm = 1.34, p = 0.247; Supplementary Figure 6), the 
diagnostic group (Qm = 3.47, p = 0.482), age (Qm = 0.67, p = 0.414; Supplementary 
Figure 7), the dose administered (Qm = 0.49, p = 0.486; Supplementary Figure 8), the 
type of task used (Qm = 1.32, p = 0.858), and the presence of ceiling effects (Qm = 
1.48, p = 0.224) did not significantly explain the between-study heterogeneity.  
 
Begg’s rank correlation test of funnel plot asymmetry did not reveal significant 
publication bias (T = -0.08, p = 0.506; Supplementary Figure 9). Rosenthal’s the file 
drawer analysis indicated a fail-safe N of 182, suggesting that 182 studies finding no 
significant effects of oxytocin on recognition of basic emotions would be required to 
reduce the observed effects to null. This exceeds Rosenthal’s criterion for this meta-
analysis (5n+10=90) suggesting that the effect was quite robust. 
 
Since the total scores in most of the included studies did not consist of all six basic 
emotions further meta-analyses were conducted to examine if he above effect was 
driven by a subset of basic emotions. Thus, we conducted six additional meta-analyses 
to investigate the effects of a single dose of intranasal oxytocin on the recognition of 
anger, fear, disgust, sadness, surprise, and happiness. Where possible the studies 
were divided into healthy and clinical subgroups, which were both inspected 
separately.  
 
Figure 4. Effect of oxytocin on overall basic emotion recognition 
-------------------------------------------------FIGURE 4--------------------------------------------------- 
 
 
4.2.3 Recognition of anger 
Ten studies investigated the effects of intranasal oxytocin on recognition of anger 
(Figure 5). Two of these studies included people with schizophrenia and BPD. 
 
 Overall, oxytocin administration did not significantly improve recognition of anger (ES 
= 0.05, Z = 1.03, p = 0.305, 95% CI [-0.05, 0.15], k = 18, N of levels = 11). When the 
groups were inspected separately, there was no significant effect of oxytocin on 
recognition of anger within the healthy (ES = 0.04, Z = 0.71, p = 0.476, 95% CI [-0.07, 
0.14], k = 14, N of levels = 9) or clinical groups (ES = 0.17, Z = 1.10, p = 0.275, 95% CI [-
0.13, 0.47], k = 4, N of levels = 2).  
 
There was no evidence of significant between-study heterogeneity (Q = 21.16, p = 
0.219, I2 = 3.45e-09%) There was also no evidence of significant publication bias on 
the Begg’s rank correlation test of funnel plot asymmetry (T = 0.03, p = 0.881; 
Supplementary Figure 10).  
 
Figure 5. Effect of oxytocin on recognition of anger. 
-------------------------------------------------FIGURE 5--------------------------------------------------- 
 
 
 
4.2.4 Recognition of fear 
Nine studies investigated the effects of intranasal oxytocin on recognition of fear 
(Figure 6). Two of the studies included people with schizophrenia and BPD.  
 
Overall, oxytocin administration significantly improved recognition of fear with a small 
effect size (ES = 0.21, Z = 2.95, p = 0.003, 95% CI [0.07, 0.34], k = 14, N of levels = 10). 
This effect was driven by a significant oxytocin-induced improvement in recognition 
of fear among the healthy individuals with a small effect size (ES = 0.24, Z = 2.63, p = 
0.009, 95% CI [0.06, 0.41], k = 10, N of levels = 8). There was no significant effect of 
oxytocin among the mixed clinical population (ES = 0.16, Z = 1.05, p = 0.295, 95% CI [-
0.14, 0.46]). 
 
The between-study heterogeneity approached significance (Q = 19.95, p = 0.096, I2 = 
20.92%) and was therefore explored further with meta-regressions. The findings from 
the meta-regressions were corrected for multiple comparisons with Bonferroni 
correction (0.05/7) and p < 0.007 was considered significant. The dose administered 
(Qm = 4.19, p = 0.041; Supplementary Figure 11), the proportion of female 
participants in the sample (Qm = 0.23, p = 0.632; Supplementary Figure 12), the 
presence of ceiling effects (Qm = 0.05, p = 0.831), age (Qm = 2.56, p = 0.109; 
Supplementary Figure 13), the type of task used (Qm = 0.78, p = 0.676), and the 
diagnostic group (Qm = 0.90, p = 0.638) did not significantly explain the between-study 
heterogeneity.   
 
There was no evidence of significant publication bias on the Begg’s rank correlation 
test of funnel plot asymmetry (T = -0.08, p = 0.747; Supplementary Figure 14). 
Rosenthal’s file drawer analysis revealed a fail-safe N of 59, suggesting that 59 
additional studies reporting no effect of oxytocin would be needed to reduce the 
observed effect to null. This exceeds Rosenthal’s criterion for this meta-analysis 
(5n+10 = 55), suggesting the effect was quite robust. 
 
Figure 6. Effect of oxytocin on recognition of fear. 
--------------------------------------------------FIGURE 6-------------------------------------------------- 
 
4.2.5 Recognition of disgust 
Four studies investigated the effects of oxytocin on the recognition of disgust (Figure 
7). Because only one of these studies included clinical populations, namely people 
with schizophrenia, it was not possible to investigate the effects of oxytocin separately 
within the healthy and clinical populations. Thus, the data was analysed across groups.  
 
The meta-analysis showed a negligible oxytocin-induced improvement in the 
recognition of disgust, which approached significance (ES = 0.18, Z = 1.73, p = 0.083, 
95% CI [-0.02, 0.39], k = 5, N of levels = 4).  
 
There was no evidence of significant between-study heterogeneity (Q = 2.07, p = 
0.722, I2 = 2.73e-08%). 
There was no evidence of significant publication bias on the Begg’s rank correlation 
test of funnel plot asymmetry (T = 0.20, p = 0.817; Supplementary Figure 15). 
 
Figure 7. Effect of oxytocin on recognition of disgust. 
---------------------------------------------------FIGURE 7------------------------------------------------- 
 
4.2.6 Recognition of sadness 
Seven studies investigated the effects of oxytocin on the recognition of sadness 
(Figure 8). As above, since only one study included a clinical group, people with 
schizophrenia, the meta-analysis was conducted across groups.  
 
The meta-analysis revealed no significant effects of oxytocin on the recognition of 
sadness (ES = 0.04, Z = 0.53, p = 0.594, 95% CI [-0.10, 0.17]). There was also no 
significant between-study heterogeneity (Q = 7.59, p = 0.474, I2 = 16.67%).  
 
There was no evidence of significant publication bias on the Begg’s rank correlation 
test of funnel plot asymmetry (T = 0.33, p = 0.260; Supplementary Figure 16). 
 
Figure 8. Effect of oxytocin on recognition of sadness.  
---------------------------------------------------FIGURE 8------------------------------------------------- 
 
 
 
4.2.7 Recognition of surprise 
Four studies investigated the effects of oxytocin on the recognition of surprise (Figure 
9). Since only one study included a clinical group, people with schizophrenia, the meta-
analysis was conducted across groups.  
 
The meta-analysis revealed no significant effect of oxytocin on the recognition of 
surprise (ES = -0.02, Z = -0.16, p = 0.874, 95% CI [-0.22, 0.19], k = 5, N of levels = 4). 
There was also no evidence of significant between-study heterogeneity (Q = 3.72, p = 
0.445, I2 = 1.90e-08%) 
There was no evidence of significant publication bias on Begg’s rank correlation test 
of funnel plot asymmetry (T = 0.20, p = 0.817; Supplementary Figure 17).  
 
Figure 9. Effect of oxytocin on recognition of surprise.  
---------------------------------------------------FIGURE 9------------------------------------------------- 
 
4.2.8 Recognition of happiness 
Twelve studies investigated the effects on intranasal oxytocin on the recognition of 
happiness. Following inspection of the standardised residuals and Cook’s distance one 
study by Xu et al. (2015) was identified as an extreme outlier (standardised res. = 2.83, 
Z = 3.27, SE = 0.87; Supplementary Table 2, Supplementary Figure 18). The meta-
analysis with the outlier present yielded no significant effect of oxytocin on the 
recognition of happiness, but there was significant between-study heterogeneity (ES 
= 0.31, Z = 1.26, p = 0.207, 95% CI [-0.17, 0.79], k = 20, N of levels = 12, Q = 93.93, p < 
0.0001, I2 = 93.34%). A meta-regression revealed that the outlier significantly 
explained the between-study heterogeneity (Qm = 51.44, p < 0.0001) leaving no 
significant residual heterogeneity (Qr = 28.36, p = 0.057). Therefore, the outlier was 
removed from further analysis. 
 
The eleven remaining studies were included in the final meta-analysis (Figure 10). Two 
of the studies included clinical groups, people with schizophrenia and BPD. Overall, 
oxytocin did not significantly improve the recognition of happiness (ES = 0.08, Z = 1.07, 
p = 0.284, 95% CI [-0.07, 0.23], k = 19, N of levels = 12). When the healthy and clinical 
groups were inspected separately, there were no differential effects among the 
healthy (ES = 0.10, Z = 1.18, p = 0.237, 95% CI [-0.06, 0.26], k = 15, N of levels = 10), or 
mixed clinical populations (ES = -0.07, Z = -0.23, p = 0.821, 95% CI [-0.72, 0.57]).  
 
The between-study heterogeneity approached significance (Q = 27.87, p = 0.064, I2 = 
33.62%) and was explored further with meta-regressions. The findings from the meta-
regressions were corrected for multiple comparisons with Bonferroni correction 
(0.05/7) and p < 0.007 was considered significant. The type of task used (Qm = 11.36, 
p = 0.010), the proportion of female participants in the sample (Qm = 0.84, p = 0.360; 
Supplementary Figure 19), age (Qm = 0.07, p = 0.789; Supplementary Figure 20), the 
dose administered (Qm = 2.67, p = 0.103; Supplementary Figure 21), the diagnostic 
group (Qm = 2.84, p = 0.242), and the presence of ceiling effects (Qm = 3.29, p = 0.070), 
did not significantly explain the between-study heterogeneity.  
 
There was no evidence of significant publication bias on the Begg’s rank correlation 
test of funnel plot asymmetry (T = -0.13, p = 0.447; Supplementary Figure 22).  
 
Figure 10. Effect of oxytocin on recognition of happiness. 
---------------------------------------------------FIGURE 10------------------------------------------------ 
 
 
4.2.9 Emotion recognition sensitivity: 
Three studies investigated the effects of intranasal oxytocin on emotion recognition 
sensitivity (Figure 11). Because only one of these studies included clinical groups, 
people with AN and BN, the meta-analysis was conducted across groups.  
 
Overall, intranasal oxytocin did not significantly influence emotion recognition 
sensitivity (ES = -0.14, Z = -1.45, p = 0.146, 95% CI [-0.34, 0.05], k = 20, N of levels = 5). 
We then investigated recognition sensitivity of each emotion separately and found 
that oxytocin did not significantly improve the sensitivity to recognise happiness (ES = 
-0.11, Z = -1.24, p = 0.216, 95% CI [-0.29, 0.07], k = 5, N of levels = 5), sadness (ES = -
0.17, Z = -1.25, p = 0.212, 95% CI [-0.43, 0.09], k = 5, N of levels = 5), fear (ES = -0.03, Z 
= -0.42, p = 0.674, 95% CI [-0.20, 0.13], k = 5, N of levels = 5), or anger (ES = -0.20, Z = 
-1.64, p = 0.100, 95% CI [-0.43, 0.04], k = 5, N of levels = 5).  
 
The between-study heterogeneity approached significance (Q = 29.31, p = 0.061, I2 = 
67.31%) and was explored further with meta-regressions. The findings from the meta-
regressions were corrected for multiple comparisons with Bonferroni correction 
(0.05/5) and p < 0.01 was considered significant. The proportion of female participants 
in the sample (Qm = 0.03, p = 0.864; Supplementary Figure 23), age (Qm = 1.27, p = 
0.261; Supplementary Figure 24), the dose administered (Qm = 0.03, p = 0.864; 
Supplementary Figure 25), and the diagnostic group (Qm = 2.03, p = 0.567) did not 
significantly explain the heterogeneity.  
 
Begg’s rank correlation test of funnel plot asymmetry revealed evidence of significant 
publication bias (T = -0.74, p < 0.0001; Supplementary Figure 26) indicating that small 
studies finding large effects were more likely to be published.  
 
Figure 11. Effect of oxytocin on emotion recognition sensitivity. 
---------------------------------------------------FIGURE 11------------------------------------------------ 
 
4.3 Effects of oxytocin on emotion expression 
Four studies investigated the effects of a single dose of intranasal oxytocin on 
expression of congruent emotions in response to emotionally provoking stimuli 
(Figure 12). Three studies included individuals with clinical conditions, including BPD, 
Schizophrenia, and AN.  
 
Overall, there was no significant effect of oxytocin on emotion expression (ES = 0.08, 
Z = 0.87, p = 0.385, 95% CI [-0.10, 0.26], k = 14, N of levels = 7). When the data was 
further inspected, the meta-analysis showed that oxytocin significantly increased the 
expression of positive emotions among the healthy individuals with a small effect size 
(ES = 0.25, Z = 2.29, p = 0.022, 95% CI [0.04, 0.47], k = 4, N of levels = 4).  Oxytocin did 
not significantly influence the expression of negative emotions among the healthy 
individuals (ES = 0.10, Z = 0.55, p = 0.585, 95% CI [-0.27, 0.47], k = 4, N of levels = 4). 
There was also no evidence of significant effects of oxytocin on the expression of 
positive or negative emotions among the clinical populations (Positive ES = 0.02, Z = 
0.13, p = 0.896, 95% CI [-0.22, 0.25], k = 3, N of levels = 3; Negative: ES = -0.08, Z -0.35, 
p = 0.726, 95% CI [-0.52, 0.36], k = 3, N of levels = 3).  
 
There was significant between-study heterogeneity (Q = 23.14, p = 0.040, I2 = 35.95%), 
which was explored further with meta-regressions. The proportion of female 
participants in the sample, age, and the dose administered individually significantly 
explained the heterogeneity (Supplementary Figures 27-29). These variables were, 
thus, entered into a full model which significantly explained the between-study 
heterogeneity (Qm = 8.80, p = 0.032) leaving no significant residual heterogeneity (Qr 
= 14.33, p = 0.158). This finding suggests that older male participants who received 
24IU of intranasal oxytocin showed greater oxytocin induced increase in facial 
expressivity. However, this meta-analysis consisted of only four studies and, thus, this 
finding should be interpreted with caution. The diagnostic group (Qm = 6.14, p = 
0.105)did not significantly explain the heterogeneity. 
 
There was no evidence of significant publication bias on the Begg's rank correlation 
test of funnel plot asymmetry (T = -0.03, p = 0.915; Supplementary Figure 30). 
However, Rosenthal’s file drawer analysis revealed a fail-safe N of 1, indicating that 
only 1 study finding no significant effects of oxytocin on emotion expression would be 
needed to reduce the observed significant effect to null. This does not exceed the 
Rosenthal’s criterion for this meta-analysis (5k+10 = 30) indicating that this finding is 
not robust and there is likely to be substantial publication bias present.  
 
Figure 12. Effect of oxytocin on emotion expression. 
---------------------------------------------------FIGURE 12------------------------------------------------ 
 
5 Discussion 
The aim of the current meta-analytic review was to investigate the effects of a single 
dose of intranasal oxytocin on interpretation and expression of emotions among 
healthy and clinical populations. Most the studies recruited only healthy individuals, 
but thirteen studies also included people with clinical disorders and two studies 
included people with substance dependence disorder. The meta-analyses revealed 
that a single dose of intranasal oxytocin significantly improved the recognition of basic 
emotions, particularly fear, but only among healthy individuals with small to negligible 
effect sizes. Oxytocin also increased the expression of positive emotions with a small 
effect size among the healthy individuals. Intranasal oxytocin did not significantly 
influence theory of mind among the healthy individuals. Although, the oxytocin-
induced improvement in basic emotion recognition approached significance, overall 
there were no significant effects on intranasal oxytocin on the interpretation or 
expression of emotions among the mixed clinical population.  
 
The oxytocin-induced increase in the expression of positive emotions in healthy 
individuals is in line with findings from previous systematic reviews and suggests that 
oxytocin plays an important role in facilitating prosocial behaviour in humans 
(Bakermans-Kranenburg and van Ijzendoorn, 2013; Churchland and Winkielman, 
2012; Guastella and MacLeod, 2012). This finding is also supported by previous work 
that has documented increased trust and cooperation particularly towards the 
members of a safe “in-group” following oxytocin administration (van Ijzendoorn and 
Bakermans-Kranenburg, 2012). Together these findings suggest that oxytocin may 
facilitate pro-social behaviour among healthy individuals. However, it is of importance 
to note that the oxytocin-induced increase in the expression of positive emotions was 
not robust, and it is likely that there was substantial publication bias present.  
 
The present findings also showed that intranasal oxytocin improved recognition of 
basic emotions, which appeared to be largely driven by oxytocin-induced significant 
improvement in fear recognition and nearly significant improvement in disgust 
recognition. These results may seem surprising in this light of the findings above. 
However, these results are in line with a previous meta-analysis, which also found that 
intranasal oxytocin improved early recognition of angry faces and late recognition of 
fearful faces among healthy individuals (Shahrestani et al., 2013). Additionally, 
intranasal oxytocin has also been found to increase attention and approach towards 
negative social-emotional stimuli, such as angry and fearful facial expressions (Clark-
Elford et al., 2015; Simon et al., 2012; Tollenaar et al., 2013).  
 
Recent systematic reviews have attempted to explain the recent emergence of similar 
seemingly contradictory findings by suggesting that the effects of intranasal oxytocin 
may be modulated by social boundaries (Olff et al., 2013; Zik and Roberts, 2015). This 
hypothesis suggests that oxytocin may be of evolutionary importance in social 
interactions, increasing pro-social behaviour towards “safe” stimuli and defensiveness 
towards “unsafe” stimuli (Olff et al., 2013; Zik and Roberts, 2015). Thus, when faced 
with positive social-emotional cues oxytocin may facilitate pro-social behaviour, trust, 
and cooperation. Conversely, when presented with unfamiliar or negative stimuli 
oxytocin administration may increase attention and alertness towards these 
potentially threatening, negative social-emotional cues. Although this hypothesis has 
not been previously linked to the effects of oxytocin on social-emotional processing, 
it is consistent with the present findings and is supported by several behavioural 
studies using investment and trust games. These studies have documented that 
intranasal oxytocin increases empathy towards “in-group” members as well as 
cooperation and compliance within the “in-group” (De Dreu and Kret, 2016; Ten 
Velden et al., 2017). Oxytocin also reduced cooperation with “out-group” members 
even when the “out-group” members are generous towards the participants 
(Daughters et al., 2017).  
 
Although, the oxytocin-induced improvement in basic emotion recognition 
approached significance, overall the present series of meta-analyses found no 
significant oxytocin-induced changes in interpretation or expression of emotions 
among the mixed clinical population. One possible explanation is that the different 
disorders included in the mixed clinical group were too heterogeneous and that there 
were too few studies with the same disorder group to draw firm conclusions. Indeed, 
there was significant heterogeneity between the diagnostic groups in the present 
series of meta-analyses. However, there were also substantial differences in effect 
size estimates between studies that included the same patient group, suggesting that 
there may be individual differences within the diagnostic groups that modulate the 
effects of oxytocin.  
 
Large-scale cohort studies have documented that clinical populations have inter-
individual variability with substantial heterogeneity in types of comorbidity and 
aetiological risk (Lamers et al., 2010; Melartin et al., 2002; Sterling et al., 2008; 
Wessman et al., 2009). A few recent systematic reviews have also suggested that the 
effects of oxytocin on social-emotional functioning may be moderated by contextual 
and individual differences (Bartz et al., 2011; Olff et al., 2013). Factors such as 
attachment style and experience of early parental care have been found to moderate 
the effects of oxytocin; those scoring low on attachment avoidance and harsh 
parenting showed greater oxytocin-induced increase in social cooperation and 
positive response to crying infants (Bakermans-Kranenburg et al., 2011; Fang et al., 
2014; Olff et al., 2013). Thus, further investigation of potential contextual and 
individual differences that may modulate the effects of oxytocin is of interest.   
 
5.1 Limitations, recommendations and future directions 
 
The majority of the studies included in the present review did not meet the sample 
size requirement for adequate statistical power to reliably detect at least a moderate 
effect of the drug. Although meta-analyses are a statistically powerful method to pool 
studies and increase statistical power (Greco et al., 2013), it is important that 
individual studies also have adequate power. This has been suggested to be a 
particularly big problem in oxytocin research and the potential source of the wide 
range of different and sometimes contradictory findings arising from different studies 
(Walum et al., 2016). These problems may go some way to explain the between-study 
heterogeneity and publication bias in the present review. Therefore, we recommend 
that future studies should recruit much larger number of participants to ensure that 
reliable effects of intranasal oxytocin can be detected. 
 
Several studies investigating the effects of a single dose of intranasal oxytocin on 
recognition of basic emotions had evidence of ceiling effects with mean accuracy 
percentages over 85%. Even though presence of ceiling effects did not have significant 
impact on the present findings, such effects make it difficult to find the true effect of 
the drug or intervention because performance is already at maximum. Future studies 
investigating the effects of intranasal oxytocin on the recognition of basic emotions, 
should opt for alternative tasks, for example presenting images where the emotion is 
less than 100% present.  
 
Seven of the meta-analyses in the present review had evidence of between-study 
heterogeneity and in three of them we were unable to identify the source of the 
heterogeneity. Previous studies have reported several confounding factors such as 
individual differences in anxiety and attachment security that can influence the effects 
of oxytocin on social-emotional processing (Bakermans-Kranenburg et al., 2011; Fang 
et al., 2014; Olff et al., 2013). The impact of these factors were not explored or 
reported in majority of the studies included in the present review meaning that it was 
not possible for us to explore the impact of these factors had on the meta-analyses. 
We recommend that future studies explore the impact of individual differences to gain 
better understanding of the impact of potential confounding factors on the effects of 
intranasal oxytocin.  
 
There has also recently been some doubt regarding the effects of intranasal oxytocin 
on social-emotional functioning in general and criticism directed at the lack of 
compelling theoretical framework to explain the contradictory findings reported thus 
far (Lane et al., 2016; Leng and Ludwig, 2016). Some important questions have also 
been raised regarding if and how intranasal oxytocin accesses the brain and in what 
quantities (Leng and Ludwig, 2016). These criticisms have become increasingly 
important to address in the light of recent replication failures (Lane et al., 2015; Radke 
and de Bruijn, 2015). We have taken some steps in the present review to introduce a 
potential theoretical framework, but several issues still remain unanswered. For 
instance, there are a number of methodological obstacles, such as individual 
differences in the nasal cavity physiology, the nasal spray formulations used, and the 
devices used to deliver the drug, that need to be considered (Quintana et al., 2016). 
Furthermore, there are uncertainties regarding the site and mechanism of action of 
exogenous intranasal oxytocin in humans due to lack of suitable radio tracers 
(Paloyelis et al., 2016). There has also been some suggestion that oxytocin has 
important effects in the periphery, moderating cardiovascular functioning and the 
peripheral cortisol response, which may influence social behaviour (Cardoso et al., 
2014b; Gutkowska et al., 2014). Further research is needed to answer these important 
questions particularly if oxytocin is to be used as a treatment enhancer to support 
clinical care. 
 
Finally, no correction for multiple comparisons was applied in the present series of 
meta-analyses. Although we took steps to combat this issue by investigating the 
robustness of all significant findings and advising caution when interpreting the 
moderator analyses, the presence of false positive findings cannot be ruled out.  
  
6 Conclusions 
The current meta-analytic review pooled studies investigating the effects of a single 
dose of intranasal oxytocin on social-cognition. There was no significant effect of 
intranasal oxytocin on interpretation or expression of emotions among the mixed 
clinical population. Intranasal oxytocin significantly improved recognition of basic 
emotions, particularly fear, and increased the expression of positive emotions, but 
only among the healthy individuals. These findings are in line with previous work that 
has found that the effects of oxytocin may be modulated by social boundaries. Further 
large-scale research is needed to better understand of the role of intranasal oxytocin 
in social-emotional processing and potential moderators of its’ effects. 
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8 Figure legends 
Figure 1. PRISMA flow chart of the study selection process for the emotion 
interpretation meta-analyses. 
 
Figure 2. PRISMA flow chart of the study selection process for the emotion 
expression meta-analyses. 
 
Figure 3. Effects of intranasal oxytocin vs. placebo on theory of mind. Positive effect 
sizes indicate improved theory of mind following oxytocin administration; negative 
effect sizes indicate reduced theory of mind following oxytocin administration. RMET 
= Reading the mind in the eyes test; MSCEIT = Mayer-Salovey-Caruso Emotional 
Intelligence Test; TASIT = The Awareness of Social Inference Test; AN = anorexia 
nervosa; ASD = autism spectrum disorder; frontotemporal dementia = FTD. 
 
Figure 4. Effect of oxytocin vs. placebo on overall basic emotion recognition. Positive 
effect sizes indicate improved emotion recognition following oxytocin 
administration; negative effect sizes indicate reduced emotion recognition following 
oxytocin administration. HEDT: 30% = Hexagon emotion discrimination task: 
morphed faces 30% intensity; HEDT: 70% = Hexagon emotion discrimination task: 
morphed faces 70% intensity; DANVA = Diagnostic Analysis of Non-Verbal Accuracy; 
ASD = Autism spectrum disorder; BPD = Borderline personality disorder; PTSD = Post-
traumatic stress disorder. Kirkpatrick, et al. 2014: a = 20IU of intranasal oxytocin, b = 
40IU of intranasal oxytocin. Campbell, et al. 2014a = young female participants, 
Campbell, et al. 2014b = young male participants, Campbell, et al. 2014c = older 
female participants, Campbell, et al. 2014d = older male participants.  
 
Figure 5. Effect of oxytocin vs. placebo on recognition of anger. Positive effect sizes 
indicate improved recognition of anger following oxytocin administration; negative 
effect sizes indicate reduced recognition of anger following oxytocin administration. 
HEDT: 30% = Hexagon emotion discrimination task: morphed faces 30% intensity; 
HEDT: 70% = Hexagon emotion discrimination task: morphed faces 70% intensity; 
BPD = Borderline personality disorder. Kirkpatrick, et al. 2014: a = 20IU of intranasal 
oxytocin, b = 40IU of intranasal oxytocin. 
 
Figure 6. Effects of oxytocin vs. placebo on recognition of fear. Positive effect sizes 
indicate improved recognition of fear following oxytocin administration; negative 
effect sizes indicate reduced recognition of fear following oxytocin administration. 
HEDT: 30% = Hexagon emotion discrimination task: morphed faces 30% intensity; 
HEDT: 70% = Hexagon emotion discrimination task: morphed faces 70% intensity. 
 
Figure 7. Effect of oxytocin vs. placebo on recognition of disgust. Positive effect sizes 
indicate improved recognition of disgust following oxytocin administration; negative 
effect sizes indicate reduced recognition of disgust following oxytocin 
administration. HEDT: 30% = Hexagon emotion discrimination task: morphed faces 
30% intensity; HEDT: 70% = Hexagon emotion discrimination task: morphed faces 
70% intensity; BPD = Borderline personality disorder. Kirkpatrick, et al. 2014: a = 
20IU of intranasal oxytocin, b = 40IU of intranasal oxytocin. 
 
Figure 8. Effect of oxytocin vs. placebo on recognition of sadness. Positive effect 
sizes indicate improved recognition of sadness following oxytocin administration; 
negative effect sizes indicate reduced recognition of sadness following oxytocin 
administration. HEDT: 30% = Hexagon emotion discrimination task: morphed faces 
30% intensity; HEDT: 70% = Hexagon emotion discrimination task: morphed faces 
70% intensity. Kirkpatrick, et al. 2014: a = 20IU of intranasal oxytocin, b = 40IU of 
intranasal oxytocin. 
 
Figure 9. Effect of oxytocin vs. placebo on recognition of surprise. Positive effect 
sizes indicate improved recognition of surprise following oxytocin administration; 
negative effect sizes indicate reduced recognition of surprise following oxytocin 
administration. HEDT: 30% = Hexagon emotion discrimination task: morphed faces 
30% intensity; HEDT: 70% = Hexagon emotion discrimination task: morphed faces 
70% intensity. 
 
Figure 10. Effect of oxytocin vs. placebo on recognition of happiness. Positive effect 
sizes indicate improved recognition of happiness following oxytocin administration; 
negative effect sizes indicate reduced recognition of happiness following oxytocin 
administration. HEDT: 30% = Hexagon emotion discrimination task: morphed faces 
30% intensity; HEDT: 70% = Hexagon emotion discrimination task: morphed faces 
70% intensity; BPD = Borderline personality disorder. Kirkpatrick, et al. 2014: a = 
20IU of intranasal oxytocin, b = 40IU of intranasal oxytocin. 
 
Figure 11. Effect of oxytocin vs. placebo on emotion recognition sensitivity. Negative 
effect sizes indicate improved emotion recognition sensitivity following oxytocin 
administration; positive effect sizes indicate reduced emotion recognition sensitivity 
following oxytocin administration. All studies used dynamic emotion recognition 
task. BN = Bulimia nervosa, AN = Anorexia nervosa. 
 
Figure 12. Effect of oxytocin vs. placebo on emotion expression. Positive effect sizes 
indicate increased emotion expression following oxytocin administration; negative 
effect sizes indicate reduced emotion expression following oxytocin administration. 
IAPS = International affective picture system; AN = anorexia nervosa; BPD = 
Borderline personality disorder. 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
 
Table 1. Study characteristics 
 
Study Dose Design Dose-
to-task 
interval 
Group 
N 
Age Task Scale Emotion ES [95% CI] Power 
≥80% 
Healthy 
Bertsch, 
et al. 
(2013) 
26 IU Between 
subjects 
40 min Healthy 
Oxytocin = 21 
Placebo = 20 
Oxytocin: 
24.6 (3.9) 
Placebo: 
24.4 (4.4) 
Emotion 
recognition: Eyes 
Accuracy 
 Anger 
0.21 [-0.41, 
0.82] 
No 
Fear 
0.37 [-0.25, 
0.99] 
Happiness 
-0.03 [-0.65, 
0.58] 
Total 
0.27 [-0.32, 
0.87] 
Emotion 
recognition: 
Mouth 
Anger 
0.41 [-0.21, 
1.03] 
Fear 
0.33 [-0.29, 
0.95] 
Happiness 
<0.01 [-0.61, 
0.61] 
Total 
0.23 [-0.31, 
0.77] 
Brune, et 
al. (2015) 
24 IU Within 
subjects 
NR Healthy 
N = 15 
25.70 
(6.40) 
Ethological Coding 
System for 
Interviews 
Expression 
Affiliation 
0.39 [-0.13, 
0.92] 
No 
Flight 
-0.18 [-0.69, 
0.33] 
20 IU Between 
subjects 
45 min Older female 
N = 34 
72.07 
(6.49) 
Emotion 
recognition 
Accuracy Total -0.16 [-0.80, 
0.48] 
No 
Campbell, 
et al. 
(2014) 
Older male 
N = 34 
0.77 [0.13, 
1.40] 
Younger female 
N = 34 
19.68 
(1.79) 
0.07 [-0.54, 
0.67] 
Younger male 
N = 34 
-0.01 [-0.62, 
0.59] 
Cardoso, 
et al. 
(2014) 
24 IU Between 
subjects 
120 min Healthy 
Oxytocin = 42 
Placebo = 40 
18-30 Mayer- Salovey-
Caruso Emotional 
Intelligence Test 
(MSCEIT) 
Accuracy Understand
ing 
emotions 
(blends) 
0.05 [-0.45, 
0.54] 
No 
Understand
ing 
emotions 
(changes) 
0.08 [-0.42, 
0.59] 
Perceiving 
emotions 
(total faces) 
-0.61 [-1.17, -
0.06] 
Chen, et 
al. (2015) 
24 IU Within 
subjects 
45 min Healthy 
N = 203 
23.5 (2.7) Dynamic emotion 
recognition 
Accuracy Anger 0.02 [-0.12, 
0.16] 
Yes 
Fear 0.13 [-0.01, 
0.26] 
Sadness -0.05 [-0.19, 
0.08] 
Happiness -0.11 [-0.25, 
0.03] 
Total 0.01 [-0.13, 
0.15] 
Anger 0.01 [-0.13, 
0.15] 
Recognitio
n 
sensitivity 
Fear 0.06 [-0.08, 
0.20] 
Sadness 0.15 [0.01, 
0.29] 
Happiness 0.05 [-0.09, 
0.19] 
Domes, 
et al. 
(2007) 
24 IU Within 
subjects 
45 min Healthy 
N = 20 
24.3 (2.2) RMET Accuracy Total 0.47 [0.01, 
0.93] 
No 
Domes, 
et al. 
(2014) 
24 IU Within 
subjects 
45 min Healthy  
N = 14 
23.6 (5.4) Emotion 
recognition: Eyes 
Accuracy Total 0.31 [-0.23, 
0.84] 
No 
Emotion 
recognition: 
Mouth 
-0.25 [-0.79, 
0.27] 
Feeser, et 
al. (2014) 
24 IU Between 
subjects 
45 min Healthy 
Oxytocin = 41 
Placebo = 41 
37.9 (4.7) Facial emotion 
recognition task  
Accuracy Anger -0.31 [-0.50, -
0.11] 
No 
Fear 0.48 [0.29, 
0.68] 
Disgust 0.38 [-0.17, 
0.94] 
Sadness 0.23 [-0.33, 
0.78] 
Surprise -0.17 [-0.73, 
0.39] 
Happiness <0.01 [-0.19, 
0.19] 
Total 0.60 [-0.16, 
1.36] 
Feeser, et 
al. (2015) 
24 IU Between 
subjects 
45 min Healthy  
Oxytocin = 36 
Oxytocin = 
27.2 (4.9) 
RMET Accuracy Total 0.62 [0.12, 
1.12] 
No 
Placebo = 35 Placebo = 
28.9 (4.8) 
Fischer-
Shofty, et 
al. (2010) 
24 IU Within 
subjects 
45 min Healthy 
N = 27 
26.93 
(3.51) 
Facial emotion 
recognition task 
Accuracy Anger -0.05 [-0.43, 
0.33] 
No 
Fear 0.50 [0.10, 
0.90] 
Disgust 0.20 [-0.18, 
0.58] 
Sadness -0.13 [-0.51, 
0.25] 
Surprise -0.10 [-0.48, 
0.28] 
Happiness 0.01 [-0.37, 
0.39] 
Total 0.15 [-0.23, 
0.53] 
Gamer, et 
al. (2010) 
24 IU Between 
subjects 
45 min Healthy 
Oxytocin = 23 
Placebo = 23 
25.0 (3.7) Facial emotion 
recognition task 
Accuracy Fear -0.20 [-0.78, 
0.38] 
No 
Happiness 0.23 [-0.35, 
0.81] 
Total 0.06 [-0.52, 
0.63] 
Kanat, et 
al. (2015) 
24IU Between 
subjects 
45 min Healthy 
Oxytocin = 21 
Placebo = 22 
23.64 
(2.81) 
Masked emotion 
recognition task 
(17ms) 
Accuracy Anger -0.15 [-0.16, 
0.96] 
No 
Happiness -0.05 [-
0.65,0.55] 
Total -0.05 [-0.65, 
0.55] 
Anger -0.32 [-0.74, 
0.41] 
Masked emotion 
recognition task 
(68ms) 
Happiness 0.18 [-0.42, 
0.77] 
Total -0.09 [-0.69, 
0.50] 
Kim, et al. 
(2015) 
40 IU Within 
subjects 
45 min Healthy 
N = 33 
22.64 
(2.28) 
Dynamic emotion 
recognition 
Recognitio
n 
sensitivity 
Anger -0.26 [-0.60, 
0.09] 
No 
Fear -0.23 [-0.58, 
0.11] 
Sadness -0.41, -0.76, -
0.05] 
Happiness 0.03 [-0.63, 
0.07] 
Kirkpatric
k, et al. 
(2014) 
20 IU Within 
subjects 
30 min Healthy 
N = 43 
24.10 
(4.10) 
Dynamic emotion 
recognition 
Accuracy Anger 0.07 [-0.23, 
0.36] 
Yes 
Fear -0.16 [-0.43, 
0.17] 
Sadness 0.02 [-0.25, 
0.35] 
Happiness -0.24 [-0.55, 
0.06] 
Total -0.05 [-0.35, 
0.25] 
40 IU Healthy  
N = 22 
23.10 
(3.50) 
Anger 0.19 [-0.23, 
0.61] 
No 
Fear 0.37 [-0.06, 
0.80] 
Sadness 0.29 [-0.14, 
0.71] 
Happiness 0.20 [-0.22, 
0.62] 
Total 0.27 [-0.15, 
0.70] 
Kirsch, et 
al. (2005) 
27 IU Within 
subjects 
50 min Healthy 
N = 15 
26.70 
(3.00) 
Emotion matching Accuracy Total 0.07 [-0.43, 
0.58] 
No 
Koch, et 
al. (2016) 
40 IU Within 
subjects 
44.68 
min 
Trauma exposed 
healthy 
N = 40 
40.00 
(10.05) 
Emotion matching Accuracy Total -0.09 [-0.40, 
0.22] 
Yes 
Korb, et 
al. (2016) 
24 IU Between 
subjects 
56 min Healthy 
Oxytocin = 30 
Placebo = 30 
Oxytocin = 
26.10 
(5.10) 
Placebo = 
23.60 
(4.10) 
Dynamic emotion: 
Happy to angry 
Expression EMG: CS 0.35 [-0.37, 
1.07] 
No 
Dynamic emotion: 
Angry to happy 
Expression EMG: ZM 0.15 [-0.39, 
0.68] 
Leppanen
, et al. 
(2017) 
40 IU Within 
subjects 
15 min Healthy 
N = 29 
26.83 
(8.54) 
RMET Accuracy Total -0.21 [-0.58, 
0.16] 
No 
Evoked facial 
expressions to film 
stimuli 
Expression Happiness 0.22 [-0.14, 
0.59] 
Sadness -0.24 [-0.61, 
0.13] 
Lischke, 
et al. 
(2012) 
24 IU Between 
subjects 
45 min Healthy 
Oxytocin = 23 
Placebo = 24 
Oxytocin = 
25.78 
(3.37) 
Placebo = 
26.38 
(3.49) 
Dynamic emotion 
recognition 
Accuracy Anger -0.16 [-0.70, 
0.37] 
No 
Fear 0.68 [0.24, 
1.12] 
Sadness -0.04 [-0.47, 
0.40]  
Happiness -0.03 [-0.57, 
0.50] 
Total 0.10 [-0.33, 
0.52] 
Recognitio
n 
sensitivity 
Anger -0.77 [ -1.25, -
0.29] 
Fear -0.58 [-1.06, -
0.09] 
Sadness -0.41 [-0.60, -
0.21] 
Happiness -0.46 [-1.05, 
0.13] 
Total -0.55 [-1.37, 
0.03]* 
Luminet, 
et al. 
(2011) 
32 IU Between 
subjects 
45 min Healthy 
Oxytocin = 30 
Placebo = 30 
21.08 
(2.13) 
RMET Accuracy Total 0.30 [-0.32, 
0.93] 
No 
Marsh, et 
al. (2010) 
24 IU Between 
subjects 
35 min Healthy  
Oxytocin = 24 
Placebo = 26 
Oxytocin = 
26.20 
(4.90) 
Placebo = 
26.60 
(5.00) 
Facial emotion 
recognition task 
Accuracy Anger 0.40 [-0.12, 
0.93] 
No 
Fear 0.32 [-0.28, 
0.91] 
Disgust 0.20 [-0.40, 
0.80] 
Sadness -0.10 [-0.69, 
0.49] 
Surprise 0.48 [-0.07, 
1.02] 
Happiness 0.65 [0.12, 
1.18] 
Total 0.36 [-0.16, 
0.89] 
Radke 
and de 
24 IU Within 
subjects 
50-65 
min 
Healthy 
N = 24 
21.50 
(1.90) 
RMET Accuracy Total 0.09 [-0.31, 
0.49] 
No 
Bruijn 
(2015) 
Riem, et 
al. (2014) 
16 IU Between 
subjects 
60 min Healthy 
Oxytocin = 25 
Placebo = 25 
19.62 
(1.47) 
RMET Accuracy Total -0.02 [-0.58, 
0.55] 
No 
Schulze, 
et al. 
(2011) 
24 IU Between 
subjects 
45 min Healthy  
Oxytocin = 28 
Placebo = 28 
24.18 
(3.12) 
Masked emotion 
recognition (mask: 
18ms) 
Accuracy   Anger 0.53 [-0.03, 
1.09] 
No 
Happiness 0.66 [0.09, 
1.23] 
Total 0.29 [-0.33, 
0.90] 
Masked emotion 
recognition (mask: 
35ms) 
Anger 0.47 [-0.11, 
1.04] 
Happiness 0.74 [0.16, 
1.31] 
Total 0.64 [-0.11, 
1.38] 
Masked emotion 
recognition (mask: 
53ms) 
Anger -0.02 [-0.45, 
0.40] 
Happiness 0.49 [0.07, 
0.92] 
Total 0.60 [-0.14, 
1.35] 
Woolley, 
et al. 
(2016) 
40 IU Within 
subjects 
45 min Healthy 
N = 33 
51.91 
(7.35) 
RMET Accuracy Total -0.06 [-0.40, 
0.28] 
No 
40 IU Within 
subjects 
30 min Healthy 
N = 31 
42.50 
(14.10) 
TASIT: Emotion 
Evaluation Test 
Accuracy Total 0.04 [-0.32, 
0.39] 
No 
Woolley, 
et al. 
(2014) 
TASIT: Social 
Inference Enriched 
(feel) 
-0.38 [-0.74, 
0.01] 
RMET 0.14 [-0.21, 
0.50] 
Woolley, 
et al. 
(2017) 
40 IU Within 
subjects 
NR Healthy 
N = 27 
42.00 
(13.70) 
Evoked facial 
expressions to 
IAPS photos 
Expression Positive 0.26 [-0.12, 
0.65] 
No 
Negative 0.49 [0.09, 
0.89] 
Xu, et al. 
(2015) 
40 IU Between 
subjects 
45 min Healthy 
Oxytocin = 29 
Placebo = 31 
Oxytocin = 
23.40 
(0.30) 
Placebo = 
22.90 
(0.30) 
RSVP task Accuracy Negative 0.76 [0.23, 
1.28]* 
No 
Happiness 3.14 [2.39, 
3.90]1 
Neutral 4.56 [3.60, 
5.52]* 
Total 2.96 [2.23, 
3.69]* 
Clinical populations     Clinical 
Aoki, et 
al. (2015) 
24 IU Within 
subjects 
40 min ASD 
N = 20 
30.8 (6.00) 
 
Sally Anne: Social-
emotional scale 
Accuracy Total 0.54 [0.07, 
1.01] 
No 
Averbeck 
(2012) 
24 IU Within 
subjects 
50 min Schizophrenia 
N = 21 
38.2 (1.8) Hexagon emotion 
discrimination 
task: morphed 
faces 30% intensity 
Accuracy Anger 0.17 [-0.26, 
0.60] 
No 
Fear 0.11 [-0.32, 
0.54] 
Disgust -0.06 [-0.49, 
0.37] 
Sadness 0.37 [-0.07, 
0.81] 
Surprise <0.01 [-0.43, 
0.43] 
Happiness 0.27 [-0.16, 
0.71] 
Total 0.58 [0.12, 
1.05] 
Hexagon emotion 
discrimination 
task: morphed 
faces 70% intensity 
Anger 0.18 [-0.25, 
0.61] 
Fear 0.42 [-0.03, 
0.87] 
Disgust 0.13 [-0.30, 
0.56] 
Sadness 0.33 [-0.11, 
0.77] 
Surprise -0.07 [-0.50, 
0.36] 
Happiness 0.16 [-0.27, 
0.59]  
Total 0.58 [0.12, 
1.05] 
Bertsch, 
et al. 
(2013) 
26 IU Between 
subjects 
40 min BPD 
Oxytocin = 19 
Placebo = 19 
Oxytocin: 
23.2 (5.3) 
Placebo: 
24.9 (5.5) 
Emotion 
recognition: Eyes 
Accuracy 
Anger 
-0.09 [-0.73, 
0.55] 
No 
Fear 
0.07 [-0.56, 
0.71] 
Happiness 
-0.66 [-1.32, -
0.01] 
Total 
-0.02 [-0.49, 
0.44] 
Emotion 
recognition: 
Mouth 
Anger 
0.39 [-0.25, 
1.03] 
Fear 
-0.24 [-0.88, 
0.39] 
Happiness 
-0.22 [-0.85, 
0.42] 
Total 
-0.14 [-0.85, 
0.58] 
Brune, et 
al. (2015) 
24 IU Within 
subjects 
NR BPD 
N = 15 
27.50 
(7.30) 
Ethological Coding 
System for 
Interviews 
Expression 
Affiliation 
-0.22 [-0.73, 
0.30] 
No 
Flight 
-0.17 [-0.68, 
0.34] 
Domes, 
et al. 
(2014) 
24 IU Within 
subjects 
45 min ASD 
N = 14 
24.0 (6.9) Emotion 
recognition: Eyes 
Accuracy 
 
Total 0.58 [0.02, 
1.15] 
No 
Emotion 
recognition: 
Mouth 
0.53 [-0.03, 
1.09] 
Guastella, 
et al. 
(2015) 
24 IU Within 
subjects 
45 min Schizophrenia 
N = 21 
37.42 
(11.14) 
Diagnostic Analysis 
of Non-Verbal 
Accuracy: Faces 
Accuracy Total 0.13 [-0.30, 
0.56] 
No 
Facial Expressions 
of Emotions Task 
-0.40 [-0.84, 
0.05] 
RMET 0.39 [-0.05, 
0.84] 
Jesso, et 
al. (2011) 
24 IU Within 
subjects 
20 min FTD 
N = 20 
64.4 (7.40) RMET Accuracy Total -0.46 [-0.92, 
0.01] 
No 
Kim, et al. 
(2015) 
40 IU Within 
subjects 
45 min AN  
N = 35 
21.97 
(8.41) 
Dynamic emotion 
recognition 
Recognitio
n 
sensitivity 
Anger 0.02 [-0.31, 
0.36] 
Yes 
Fear 0.14 [-0.19, 
0.47] 
Sadness -0.01 [-0.34, 
0.33] 
Happiness 0.03 [-0.35, 
0.31] 
BN 
N = 34 
23.03 
(5.17) 
Anger -0.36 [-0.71, -
0.01] 
Yes 
Fear -0.03 [-0.37, 
0.31] 
Sadness -0.39 [-0.74, -
0.04] 
Happiness 0.03 [-0.58, 
0.11] 
Koch, et 
al. (2016) 
40 IU Within 
subjects 
44.68 
min 
PTSD 
N = 36 
39.93 
(9.58) 
Emotion matching Accuracy Total 0.36 [0.03, 
0.70] 
Yes 
Leppanen
, et al. 
(2017) 
40 IU Within 
subjects 
15 min AN 
N = 30 
26.2 (6.82) RMET Accuracy Total 0.10 [-0.26, 
0.46] 
No 
Evoked facial 
expressions to film 
stimuli 
Expression Happiness -0.04 [-0.40, 
0.31] 
Sadness -0.40 [-0.77, -
0.03] 
MacDona
ld, et al. 
(2013) 
40 IU Within 
subjects 
75 min Depression 
N = 17 
43.65 
(12.20) 
RMET Accuracy Total 0.50 [-0.01, 
1.00] 
No 
Mitchell, 
et al. 
(2016) 
40 IU Within 
subjects 
30 min Alcohol 
dependence 
N = 32 
28.90 
(7.15) 
RMET Accuracy Total 0.24 [-0.12, 
0.60] 
No 
Woolley, 
et al. 
(2016) 
40 IU Within 
subjects 
45 min Opioid 
dependence 
N = 33 
57.97 
(8.88) 
RMET Accuracy Total -0.51 [-0.88, -
0.15] 
No 
Woolley, 
et al. 
(2014) 
40 IU Within 
subjects 
30 min Schizophrenia 
N = 29 
44.60 
(10.70) 
TASIT: Emotion 
Evaluation Test 
Accuracy Total -0.02 [-0.38, 
0.35] 
No 
TASIT: Social 
Inference Enriched 
(feel) 
0.35 [-0.02, 
0.73] 
RMET -0.02 [-0.38, 
0.35] 
Woolley, 
et al. 
(2017) 
40 IU Within 
subjects 
NR Schizophrenia 
N = 25 
43.20 
(11.00) 
Evoked facial 
expressions to 
IAPS photos 
Expression Positive 0.23 [-0.17, 
0.63] 
No 
Negative 0.33 [-0.07, 
0.73] 
1 Influential outlier. Excluded from meta-analysis. 
* Not included in meta-analysis. 
ES = effect size; IU = international unit; NR = not reported; AN = anorexia nervosa, ASD = autism spectrum disorder, BN = bulimia 
nervosa, BPD = borderline personality disorder, PTSD = posttraumatic stress disorder RMET = reading the mind in the eyes test; TASIT 
= The Awareness of Social Inference Test; IAPS = International Affective Picture System. “No” in the power column indicates the study 
did not reach the sample size requirement for adequate statistical power and “Yes” in the power column indicates the study reached the 
sample size requirement for adequate statistical power. 
 
 
 
 
 
 
 
